Novavax Inc
NASDAQ:NVAX

  • LAST PRICE
    15.5000
  • TODAY'S CHANGE (%)
    0.3500 (2.3102%)
  • Bid / Lots
    15.5000/ 32
  • Ask / Lots
    15.7000/ 1
  • Open / Previous Close
    15.4700 / 15.1500
  • Day Range
    14.9619
    15.9600
  • 52 Week Range
    3.5324
    17.4000
  • Volume
    12,749,506

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
NVAX
Novavax Inc
2.1B
-4.9x
---
PTCT
PTC Therapeutics Inc
2.8B
-4.8x
---
ACAD
ACADIA Pharmaceuticals Inc
2.6B
-1,181.0x
---
AZTA
Azenta Inc
2.7B
-18.6x
---
GH
Guardant Health Inc
2.8B
-6.5x
---
PIII
P3 Health Partners Inc
189.7M
-1.0x
---
As of 2024-05-24

Company Information

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Contact Information

Headquarters
700 Quince Orchard RoadGAITHERSBURG, MD, United States 20878
Phone
240-268-2000
Fax
302-636-5454

Executives

Independent Chairman of the Board
James Young
President, Chief Executive Officer, Director
John Jacobs
President, Chief Operating Officer
John Trizzino
Chief Financial Officer, Executive Vice President, Treasurer
James Kelly
President - Research and Development
Filip Dubovsky

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.1B
Revenue (TTM)
$996.6M
Shares Outstanding
140.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.93
EPS
$-3.18
Book Value
$-5.14
P/E Ratio
-4.9x
Price/Sales (TTM)
2.1
Price/Cash Flow (TTM)
---
Operating Margin
-39.99%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.